BACKGROUND: Cut-off scores for determining positivity of biomarkers detected by immunohistochemistry are often set arbitrarily and vary between reports. AIMS: To evaluate the performance of receiver operating characteristic (ROC) curve analysis in determining clinically important cut-off scores for a novel tumour marker, the receptor for hyaluronic acid mediated motility (RHAMM), and show the reproducibility of the selected cut-off scores in 1197 mismatch-repair (MMR) proficient colorectal cancers (CRC). METHODS: Immunohistochemistry for RHAMM was performed using a tissue microarray of 1197 MMR-proficient CRC. Immunoreactivity was scored using a semi-quantitative scoring method by evaluating the percentage of positive tumour cells. ROC curve analysis was performed for T stage, N stage, tumour grade, vascular invasion and survival. The score with the shortest distance from the curve to the point with both maximum sensitivity and specificity, i.e. the point (0.0, 1.0), was selected as the cut-off score leading to the greatest number of tumours correctly classified as having or not having the clinical outcome. In order to determine the reliability of the selected cut-off scores, 100 bootstrapped replications were performed to resample the data. RESULTS: The cut-off score for T stage, N stage, tumour grade and vascular invasion was 100% and that for survival 90%. The most frequently selected cut-off score from the 100 resamples was also 100% for T stage, N stage, tumour grade, and vascular invasion and 90% for survival. CONCLUSIONS: ROC curve analysis can be used as an alternative method in the selection and validation of cut-off scores for determining the clinically relevant threshold for immunohistochemical tumour positivity.
BACKGROUND: Cut-off scores for determining positivity of biomarkers detected by immunohistochemistry are often set arbitrarily and vary between reports. AIMS: To evaluate the performance of receiver operating characteristic (ROC) curve analysis in determining clinically important cut-off scores for a novel tumour marker, the receptor for hyaluronic acid mediated motility (RHAMM), and show the reproducibility of the selected cut-off scores in 1197 mismatch-repair (MMR) proficient colorectal cancers (CRC). METHODS: Immunohistochemistry for RHAMM was performed using a tissue microarray of 1197 MMR-proficient CRC. Immunoreactivity was scored using a semi-quantitative scoring method by evaluating the percentage of positive tumour cells. ROC curve analysis was performed for T stage, N stage, tumour grade, vascular invasion and survival. The score with the shortest distance from the curve to the point with both maximum sensitivity and specificity, i.e. the point (0.0, 1.0), was selected as the cut-off score leading to the greatest number of tumours correctly classified as having or not having the clinical outcome. In order to determine the reliability of the selected cut-off scores, 100 bootstrapped replications were performed to resample the data. RESULTS: The cut-off score for T stage, N stage, tumour grade and vascular invasion was 100% and that for survival 90%. The most frequently selected cut-off score from the 100 resamples was also 100% for T stage, N stage, tumour grade, and vascular invasion and 90% for survival. CONCLUSIONS: ROC curve analysis can be used as an alternative method in the selection and validation of cut-off scores for determining the clinically relevant threshold for immunohistochemical tumour positivity.
Authors: Shandra Bipat; Afina S Glas; Frederik J M Slors; Aeilko H Zwinderman; Patrick M M Bossuyt; Jaap Stoker Journal: Radiology Date: 2004-07-23 Impact factor: 11.105
Authors: J-P Spano; C Lagorce; D Atlan; G Milano; J Domont; R Benamouzig; A Attar; J Benichou; A Martin; J-F Morere; M Raphael; F Penault-Llorca; J-L Breau; R Fagard; D Khayat; P Wind Journal: Ann Oncol Date: 2005-01 Impact factor: 32.976
Authors: O Nehls; B Klump; K Holzmann; G Lammering; F Borchard; H H Gruenagel; V Gaco; M Gregor; R Porschen Journal: Cancer Date: 1999-06-15 Impact factor: 6.860
Authors: Samar Al-Homoud; Sanjay Purkayastha; Omer Aziz; Jason J Smith; Michael D Thompson; Ara W Darzi; Jeffrey D Stamatakis; Paris P Tekkis Journal: Surg Oncol Date: 2004 Aug-Nov Impact factor: 3.279
Authors: Carolina Muriel López; Emilio Esteban; Aurora Astudillo; Pablo Pardo; Jose Pablo Berros; Marta Izquierdo; Guillermo Crespo; Paula J Fonseca; Miguel Sanmamed; Pablo Martínez-Camblor Journal: Invest New Drugs Date: 2012-05-27 Impact factor: 3.850
Authors: A Lugli; E Karamitopoulou; I Panayiotides; P Karakitsos; G Rallis; G Peros; G Iezzi; G Spagnoli; M Bihl; L Terracciano; I Zlobec Journal: Br J Cancer Date: 2009-09-15 Impact factor: 7.640
Authors: Norberto A Gandini; María E Fermento; Débora G Salomón; Diego J Obiol; Nancy C Andrés; Jean C Zenklusen; Julián Arevalo; Jorge Blasco; Alejandro López Romero; María M Facchinetti; Alejandro C Curino Journal: Tumour Biol Date: 2014-03